Mira Pharmaceuticals Inc (MIRA)
Mira Pharmaceuticals, Inc. is a NASDAQ-listed common stock company focused on pre-clinical pharmaceutical development. Its pipeline currently centers on two neuroscience programs aimed at neurologic and neuropsychiatric conditions. The company holds exclusive U.S., Canadian, and Mexican rights to Ketamir-2, a patent-pending oral ketamine analog being studied for its potential to act quickly in treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. It is also developing MIRA-55, an oral pharmaceutical marijuana product under investigation for use in adults with anxiety and cognitive decline, including symptoms associated with early-stage dementia. The company was incorporated in 2020 and is based in Miami, Florida. It previously operated under the name MIRA1a Therapeutics, Inc.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MIRA
|
$1.20
|
28.7% Upside
|
Undervalued
|
$17.75 1,804.9% Upside
|
—
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
September 2, 2026
|
-1.3x
|
4.3x
|
—
|
38.66 M
|
30.46 M
|
0.0%
|
83.4%
|
193.9
|
—
|
13.5%
|
